91ÊÓƵרÇø

³ú³ó²¹´Ç³ó³Ü¾±±è¾±²Ô²µ³ó³Ü²¹²Ô±ô¾±²¹´Ç²â¾±´Ú³Ü£¬³ú³Ü´Ç±ô¾±²¹´Ç³æ¾±³Ü³ú¾±²ú²¹»å´Ç²Ô²µ³æ¾±´Ú±ð²Ô±ô±ð¾±±ô¾±²¹´Ç²â¾±³æ¾±²¹£¬°ì²¹²Ô°ì²¹²Ô»å³Ü³¾²¹¾±±ô¾±²¹´Ç²õ³ó²¹£¬³ó³Ü²¹²Ô±ç³Ü±ð²õ³ó²¹¡£±ô³Ü´Ç²õ³ó²¹±ô¾±²¹´Ç±ç¾±²¹²Ô²µ°ù±ð²Ô²ú±ð¾±³Ù´Ç²Ô²µ£¬³ú³ó²¹´Ç»å²¹¾±±ç¾±²¹²Ô±ô²¹¾±»å¾±²¹´Ç²â²¹²Ô»å±ð°ù±ð²Ô¡£

»ò(±á³Ü´Ç)Ðí(³Ý³Ü)ÔÚ(´Ü²¹¾±)Ëû(°Õ²¹)ÃÇ(²Ñ±ð²Ô)ÑÛ(³Û²¹²Ô)ÖÐ(´Ü³ó´Ç²Ô²µ)£¬Ê¼(³§³ó¾±)ÖÕ(´Ü³ó´Ç²Ô²µ)̤(°Õ²¹)̤(°Õ²¹)ʵ(³§³ó¾±)ʵ(³§³ó¾±)¡¢ÇÚ(²Ï¾±²Ô)ÇÚ(²Ï¾±²Ô)¿Ò(°­±ð²Ô)¿Ò(°­±ð²Ô)×ö(´Ü³Ü´Ç)ÊÂ(³§³ó¾±)µÄ(¶Ù±ð)ÈË(¸é±ð²Ô)ºÜ(±á±ð²Ô)ɵ(³§³ó²¹)¡£

zhebiaomingweishengsuB6zaiduiputaotangdefanyingzhongfahuizhuojinhuashangbaoshoudezuoyong¡£¡°diyifanying¡±xibaokenenghuichanshengweishengsuB6£¬bingxiangqiyu¦ÂxibaotigongweishengsuB6£¬yidiaojieqihuoxing¡£ruhequfenfeidianxingCMLyuqitagusuizengzhixingzhongliuyuanchuang2020-09-12 17:53¡¤yimaitongxueyekezuozhe£ºlanjingxiaohubenwenweizuozheshouquanyimaitongfabu£¬weijingshouquanqingwuzhuanzai¡£feidianxingmanxingsuixibaixuebing(aCML)£¬BCR-ABL1(£­)£¬shiyizhonghanjiandexueyeexingzhongliu£¬shuyuWHOgusuizhongliufenleizhongdegusuizengshengyichang/gusuizengzhixingzhongliu(MDS/MPN)¡£aCMLzuichubeimingmingwei¡°feidianxing¡±xingshidemanxingsuixibaixuebing(CML)£¬jishinianlaiaCMLdezhenduanbiaozhunfashengliaoxianzhubianhua¡£raner£¬aCMLdezhenduanquefatezhengxing£¬duiqifenzijiyintupuderiyiliaojieyouzhuyuqufenaCMLyuqitaMDS/MPNheMPNs£¬yibianzaoqiqidongzhiliaohegaishanyuhou¡£aCMLdelinchuanghexingtaibiaoxingaCMLhuanzhebiaoxianchugusuizengshengtezheng£¬baokuobaixibaozengduohepizhongda£¬kebanyoupinxuehexuexiaobanjianshao¡£WBCjishu¡Ý13¡Á109/L¡£waizhouxuezhongcunzaizhishao10%deweichengshulixibao£¨baokuozaoyoulixibao¡¢zhongyoulixibaohewanyoulixibao£©£¬yizhongdulixibaoshengchengzhangaiweitezheng¡£bucunzaidanhexibaozengduo£¨waizhouxuedanhexibao2%£©¡£xibaohuaxueranse£¬rufeiteyixingzuomei(NSE)youzhuyuzaiyinanbinglizhongjiancedanhexibao¡£lingyigegengzhuguandexingtaixuequbieshiaCMLcunzaigengyanzhongdelixibaofayubuliang£¬jinguanquefapinggufayubuliangyanzhongchengdudejutizhinan¡£xuyaojinxingtieranseyipaichubanyouhuanxingtieliyouxibaohexuexiaobanzengduodeMDS/MPN-RS-T¡£zaiyizengzhitezhengweizhu£¬qieyizhongxinglixibaoweizhudehuanzhezhong£¬CSF3RtubianyingqianglietishiCNL¡£qufenaCMLyuMDS/MPN-Ujiaoweikunnan¡£aCMLhuanzhedezhongweiWBCjishuxianzhushenggao£¬danfeijueduitezheng¡£chixuxingdanhexibaozengduotishiCMML¡£TET2+SRSF2tubianduiCMMLjuyouxiangduiteyixing£¬jinguanliangzhezaiaCMLzhongjunkejian¡£yizhongxindeaCMLzhenduanliuchengxiaojieyouyufabinglvdi¡¢zhenduanbiaozhunbuduangengxinhequefafenziyichuanxuedelijie£¬feidianxingmanxingsuixibaixuebingyizhishiyizhongnanyizhenduandeMDS/MPN¡£suizhuoduijiyinzudashujudebuduanwajue£¬yifaxianSETBP1heETNK1defanfutubianduiaCMLyoutishizuoyong£¬keyijieheshiyanshihexingtaixuejieguolaiqufenaCMLheqitafeichengyinxinggusuizengzhixingzhongliu¡£ranertubiandetongshifashengshifouhuigaibianaCMLdejibingbiaoxinghezhiliaofanyingshangbumingque¡£cankaowenxian£º1. Orazi A, Bennett JM, Bain BJ, et al. Atypical chronic myeloid leukaemia, BCR-ABL1 negative. In: Swerdlow SH, Campo E, Harris NL, et al, editors. WHO Classification of tumors of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2017. pp. 87¨C89.2. Kantarjian HM, Keating MJ, Walters RS, et al. Clinical and prognostic features of Philadelphia chromosome-negative chronic myelogenous leukemia. Cancer 1986; 58:2023¨C2030.3. Kurzrock R, Bueso-Ramos CE, Kantarjian H, et al. BCR rearrangement-negative chronic myelogenous leukemia revisited. J Clin Oncol 2001; 19:2915¨C2926.4. Giri S, Pathak R, Martin MG, Bhatt VR. Characteristics and survival of BCR/ABL negative chronic myeloid leukemia: a retrospective analysis of the Surveillance, Epidemiology and End Results database. Ther Adv Hematol 2015; 6:308¨C312.5. Sadigh S, Hasserjian RP, Hobbs G. Distinguishing atypical chronic myeloid leukemia from other Philadelphia-negative chronic myeloproliferative neoplasms. Curr Opin Hematol. 2020;27(2):122-127.6. Itonaga H, Ota S, Ikeda T, et al. Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: a retrospective nationwide study in Japan. Leuk Res 2018; 75:50¨C57.7. Meggendorfer M, Haferlach T, Alpermann T, et al. Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia. Haematologica 2014; 99:e246.8. Wang SA, Hasserjian RP, Fox PS, et al. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood 2014; 123:2645 -2651.9. Patnaik MM, Barraco D, Lasho TL, et al. Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. Am J Hematol 2017; 92:542¨C548.10. Schwartz LC, Mascarenhas J. Current and evolving understanding of atypical chronic myeloid leukemia. Blood Rev 2019; 33:74¨C81.11. Faisal M, Stark H, Busche G, € et al. Comprehensive mutation profiling and mRNA expression analysis in atypical chronic myeloid leukemia in comparison with chronic myelomonocytic leukemia. Cancer Med 2019; 8:742¨C750.12. Zhang H, Wilmot B, Bottomly D, et al. Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. Blood 2019; 134:867¨C879.13. Hasserjian RP. Illuminating neutrophilic myeloid neoplasms. Blood 2019; 134:846¨C848.14. Steer EJ, Cross NC. Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta. Acta Haematol 2002; 107:113¨C122.15. Cheah CY, Burbury K, Apperley JF, et al. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood 2014; 123:3574¨C3577.16. Meggendorfer M, Roller A, Haferlach T, et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood 2012; 120: 3080¨C3088.

Óë(Yu)´Ë(Ci)ͬ(Tong)ʱ(Shi)£¬¶«(Dong)ÄÏ(Nan)ÑÇ(Ya)µØ(Di)Çø(Qu)¶à(Duo)¹ú(Guo)¶Ô(Dui)ÐÂ(Xin)ÄÜ(Neng)Ô´(Yuan)Æû(Qi)³µ(Che)·¢(Fa)Õ¹(Zhan)¸ø(Gei)Óè(Yu)ÁË(Liao)³ä(Chong)×ã(Zu)µÄ(De)Õþ(Zheng)²ß(Ce)Ö§(Zhi)³Ö(Chi)¡£Ó¡(Yin)Äá(Ni)·½(Fang)Ãæ(Mian)£¬¼Æ(Ji)»®(Hua)2023 Äê(Nian)Ϊ(Wei)ÿ(Mei)Á¾(Liang)ÔÚ(Zai)Ó¡(Yin)Äá(Ni)¹ú(Guo)ÄÚ(Nei)Éú(Sheng)²ú(Chan)µÄ(De)µç(Dian)¶¯(Dong)Æû(Qi)³µ(Che)Ìá(Ti)¹©(Gong)×î(Zui)¸ß(Gao)8000Íò(Wan)Ó¡(Yin)Äá(Ni)¬(Lu)±È(Bi)µÄ(De)²¹(Bu)Ìù(Tie)£¬Îª(Wei)ÿ(Mei)Á¾(Liang)»ì(Hun)ºÏ(He)¶¯(Dong)Á¦(Li)Æû(Qi)³µ(Che)Ìá(Ti)¹©(Gong)Ô¼(Yue)4000Íò(Wan)Ó¡(Yin)Äá(Ni)¬(Lu)±È(Bi)µÄ(De)²¹(Bu)Ìù(Tie)£¬Ö¼(Zhi)ÔÚ(Zai)µ½(Dao)2030Äê(Nian)½«(Jiang)µ±(Dang)µØ(Di)µç(Dian)¶¯(Dong)Æû(Qi)³µ(Che)µÄ(De)Ïú(Xiao)Á¿(Liang)Ìá(Ti)¸ß(Gao)Èý(San)±¶(Bei)£¬Í¬(Tong)ʱ(Shi)Òý(Yin)Èë(Ru)µç(Dian)¶¯(Dong)Æû(Qi)³µ(Che)ÖÆ(Zhi)Ôì(Zao)ÉÌ(Shang)ÔÚ(Zai)µ±(Dang)µØ(Di)Ͷ(Tou)×Ê(Zi)£¬ÒÔ(Yi)ʵ(Shi)ÏÖ(Xian)½¨(Jian)Á¢(Li)±¾(Ben)ÍÁ(Tu)¹©(Gong)Ó¦(Ying)Á´(Lian)µÄ(De)Ô¸(Yuan)¾°(Jing)¡£

ÎÒÃÇÅ׿ªÕâ¼þÊÂÇ鲻̸£¬Âíδ¶¼µÄÈ·ÊǺÜÓÐÈ˸ñ÷ÈÁ¦µÄ£¬ÌرðÊÇÔÚ½²ÀúÊ·½²¹Å´úһЩÎï¼þ¹Å¶­µÄʱºò£¬ÕæµÄÄÜÈÃÈ˾²ÏÂÐÄÀ´ÌýÒ»Ìý£¬Ñ§Ò»Ñ§¡£È»¶øÕâ´ÎÊÂÇé·¢ÉúÖ®ºó£¬´ó¼ÒÏÔÈ»¸Ðµ½Ê®·Ö³Ô¾ª£¬±Ï¾¹Âíδ¶¼¸øÈ˵ĸоõÊDZȽÏÕýÄÜÁ¿µÄ£¬¶øÇÒÓÐÕâô¶àµÄ¹Å¶­Êղأ¬±¾ÉíÒ²²»²îÇ®£¬Ôõô¿ÉÄÜ»áΪÁËÕâ80¸öÈ˵Ť×ʲÃÔ±£¬ÄÖ³öÕâô´óµÄÊÂÇéÄØ£¿¡°°ÂÃÃÑÝÕâÑùµÄ½ÇÉ«µ½µ×ÊÇÔõôÏëµÄ£¿¡±±¦±¦Á½¸öÊÖָʹ³åÒ½ÁªÃ½Ì屦Óñ´Ó±¦îÎÉíÌåÀïÍ˳öÀ´ºìÂ¥´º-à»ÊÀáÛ·æ-92°ìÑÔÇéС˵Íø

Õâ¸öÃû×Ö¿´ÆðÀ´Ê®·Ö¸ß´óÉÏ¿Éʵ¼ÊÉϾÍÊÇÒ»ÖÖÔì¼ÙµÄÔ­²ÄÁÏ

ÉùÃ÷£º¸ÃÎĹ۵ã½ö´ú±í×÷Õß±¾ÈË£¬ËѺüºÅϵÐÅÏ¢·¢²¼Æ½Ì¨£¬ËѺü½öÌṩÐÅÏ¢´æ´¢¿Õ¼ä·þÎñ¡£